Fertility Treatment in PCOS Patients with Elevated Testosterone

Initial Foundation: Lifestyle Modification

The American College of Obstetricians and Gynecologists recommends that PCOS patients with hyperandrogenism seeking fertility start with lifestyle modification targeting 5-10% weight loss, then proceed directly to clomiphene citrate as first-line ovulation induction, with letrozole as an increasingly preferred alternative that demonstrates superior live birth rates 1, 2
Target a 500-750 kcal/day energy deficit, as weight loss of even 5% improves ovulation and pregnancy rates 1, 2, 3
Prescribe at least 250 minutes/week of moderate-intensity exercise for weight loss, which benefits PCOS even without weight loss 1, 2

The American College of Obstetricians and Gynecologists recommends clomiphene citrate as first-line therapy, with approximately 80% of PCOS patients ovulating and 50% of those conceiving 1, 2
Standard dosing of clomiphene citrate starts at 50 mg daily for 5 days, and can be escalated to 100 mg, then 150 mg in subsequent cycles if ovulation does not occur 1
Letrozole demonstrates superior outcomes compared to clomiphene citrate, with higher live birth rates and pregnancy rates 1, 2

Low-dose gonadotropin therapy is preferred over high-dose protocols due to higher monofollicular development rates and lower OHSS risk 1, 2

Metformin improves ovulation frequency and should be used as adjunct to lifestyle modification and ovulation induction agents, not as primary fertility treatment 1, 4
Metformin appears safe in pregnancy and may reduce miscarriage rates 1, 3
GLP-1 agonists show promise for weight reduction and metabolic improvement when combined with lifestyle interventions 2

All PCOS patients attempting conception require metabolic surveillance regardless of weight or testosterone levels, including screening for glucose intolerance and obtaining fasting lipid profile 1, 2, 4

Weight loss and exercise decrease androgen levels, and metformin decreases circulating androgens 1, 2, 4
Successful ovulation induction itself improves hormonal milieu 1

Do not use spironolactone as monotherapy in fertility patients due to contraindication in pregnancy 3
Do not exceed clomiphene dosage/duration recommendations due to worsening endometrial receptivity 2
Do not delay lifestyle intervention, as it must be the foundation of treatment 2, 3

The American Academy of Family Physicians recommends clomiphene citrate as a first-line pharmacologic treatment, with an 80% ovulation rate and 50% conception rate among ovulators, but inositol offers distinct advantages, including no risk of multiple pregnancy and no weight gain, with a favorable safety profile compared to metformin 5
Inositol has a favorable safety profile compared to metformin, which has uncertain effects on early pregnancy, and offers pregnancy rates equivalent or superior to metformin without moderate-to-severe side effects, with no weight gain, unlike thiazolidinediones which tend to increase weight 5